GOUT-FLARE: 50-75% of patients flare during ULT initiation — executable 7-domain risk prediction per ACR 2020

Paradoxical gout flares during urate-lowering therapy initiation are the primary cause of treatment discontinuation. GOUT-FLARE scores 7 domains: urate gap, flare history, ULT phase, prophylaxis, renal function, tophi, comorbidities. Integrates ACR 2020 guidelines (FitzGerald DOI:10.1002/acr.24180) including HLA-B*5801 screening for allopurinol. Monte Carlo uncertainty. Not validated in clinical cohort. Authors: Zamora-Tehozol EA (ORCID:0000-0002-7888-3961), DNAI.